Laura Nichols
Vice President, Investor Relations
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q2 2025 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q2 2025 earnings conference call, held 2025-05-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Todd Brady
President and Chief Executive Officer
Catherine Novak
Analyst, Jones Trading
Tom Schrader
Analyst, BTIG
Matthew Caulfield
Analyst, Pages Windrider
Yael Jan
Analyst, Lalo & Company
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.337 Hello, everyone, and welcome to the Aldira Therapeutics Phase 3 data call. 00:00:04.337 -- 00:00:07.501 My name is Carla, and I will be coordinating your call today. 00:00:07.501 -- 00:00:11.285 During the presentation, you will have the opportunity to ask questions by pressing star 00:00:11.285 -- 00:00:15.931 followed by 1 on your telephone keypad. If you change your mind, please press star followed 00:00:15.931 -- 00:00:20.878 by 2. I would now like to hand you over to Laura Nichols to begin. 00:00:20.878 -- 00:00:24.119 Laura, please go ahead when you're ready. 00:00:24.763 -- 00:00:29.472 Thank you, and good morning, everyone. Yesterday, we issued a press release announcing 00:00:29.472 -- 00:00:34.698 achievement of the primary endpoint of a Phase III dry eye chamber trial 00:00:34.698 -- 00:00:40.165 of Aproxilab, an investigational new drug for the treatment of dry eye disease. 00:00:40.165 -- 00:00:45.311 A copy of the press release is available on the Investor in Media section of our website, 00:00:45.311 -- 00:00:47.311 www.aldera.com. 00:00:48.555 -- 00:00:53.084 The press release contains important information and should be read and considered in 00:00:53.084 -- 00:00:58.651 conjunction with the slides presented in prepared remarks made on today's call. 00:00:58.651 -- 00:01:01.995 With me today to discuss the top line results is Dr. 00:01:01.995 -- 00:01:07.261 Todd Brady, President and Chief Executive Officer of LDRRA. 00:01:07.261 -- 00:01:12.447 Turning to slide two. This presentation and various remarks which may be made during 00:01:12.447 -- 00:01:17.693 this presentation contain forward-looking statements regarding LDRRA, its investigational 00:01:17.693 -- 00:01:23.143 drug candidate, Roproxilab, and its plans...